Figure 1.
Overview of the distribution of colorectal cancers in the contemporary dataset.
Figure 2.
Overview of the distribution of colorectal cancers in the historic dataset.
Table 1.
Clinico-pathological parameters of the contemporary and historic colorectal cancer datasets.
Table 2.
Lymph node yield for all colorectal cancers 2005–2012.
Table 3.
Lymph node yield in colorectal cancer analysed by year.
Figure 3.
The frequency of individual tumour stages in colon cancer from 1975–2012.
The 2005–2012 data excludes screen detected cancers thus allowing direct comparison with the historic data set prior to the introduction of the bowel cancer screening programme. Rectal cancers have also been excluded as the introduction of neo-adjuvant therapy for rectal cancers excludes the direct comparability of rectal cancer staging.
Figure 4.
The tumour stage frequency distribution of colorectal cancer 2005–2012.
A. All colorectal cancers, B. cases that did not receive neoadjuvant therapy, C. colon cancers, D. colon cancers excluding bowel screening detected cases.
Table 4.
Trends in colorectal cancer stage 1975–2012.
Figure 5.
Trends in frequency of Dukes C colorectal cancers and mean lymph node yield 2005–2012.
A. All colorectal cancers, B, cases that did not receive neoadjuvant therapy, C. colon cancer, D. colon cancer excluding screen detected cases. For all groups there is a highly significant trend to increasing lymph node yield over this time period without a corresponding trend to an increased proportion of Dukes C/lymph node positive cases. The equations for the linear trend lines for Dukes C cancer and lymph node yield respectively are shown below the corresponding graph.